Healthcare solutions company Owens & Minor Inc (NYSE:OMI) on Tuesday introduced ByramConnect, a digital health platform designed to support Byram Healthcare customers managing diabetes and other chronic conditions.
Powered by the Welldoc App, the platform offers AI-driven health coaching, self-tracking and personalised insights to improve patient outcomes.
ByramConnect is an FDA-cleared class II software as a medical device intended for patients with type 1 or type 2 diabetes. Clinical studies show that users experienced improvements in A1C levels, blood pressure and weight management. The app integrates data from fitness trackers, glucose monitors, blood pressure monitors and other connected health devices.
Key features include AI-driven digital coaching, diet and nutrition support, GLP-1 medication tracking and mental well-being guidance. Patients receive personalised health reports with actionable insights to share with their healthcare providers.
The platform is available at no additional cost exclusively to Byram Healthcare diabetes customers. Eligible users will receive email invitations with an access code to download the app on iOS and Android devices.
Galmed reports positive preclinical results for Aramchol in prostate cancer
Galderma receives EU approval for Restylane Shaype facial shaping injectable
Acarix's CADScor System receives UAE regulatory approval
Amsino receives Vizient contract for enteral syringes
Sisram Medical introduces Titanium Prime treatment concept in Hong Kong SAR
Proteotype unveils Alchemi platform for blood-based multi-cancer test Enlighten
Insulet expands European footprint with Omnipod 5 and Omnipod Discover launch in Spain
Frontier IP portfolio company InSignals wins EU grant and launches Parkinson's app
PharmaResearch to acquire CG USA to support North American expansion of REJURAN Cosmetics
United Therapeutics wins FDA approval for LungFX ex vivo lung perfusion device
Natera Signatera gains PMDA approval in Japan for colorectal cancer testing